Prednisolone,
does it really help with Analgesic equivalence to indomethacin or naproxen in adult acute gout?
research showsThe grade is C. Active-control equivalence trials found pain reduction similar to indomethacin or naproxen. No randomized trial of systemic glucocorticoid alone versus placebo in acute gout was identified, so the evidence supports comparative equivalence rather than absolute analgesic efficacy; the score is C with 54 points.
ads claimSimilar performance against an NSAID should not be restated as two direct placebo-controlled demonstrations of absolute benefit. Its role as an alternative when NSAIDs are unsuitable also needs clinical context.
Useful facts when choosing a product
- Prednisolone is a systemic glucocorticoid prescription drug.
- Existing prednisolone verdicts concern Bell's palsy, alcoholic hepatitis, lower respiratory infection, and sudden hearing loss rather than acute gout.
- The trial regimens were short courses of about five days and do not replace long-term urate-lowering therapy.
Chamgap Semantic Classification Code
Candidate index · review held
M.prednisolone.oral.analgesic-equivalence-to-indomethacin-or-naproxen-acute-gout.equivalent.MULTIMedicinal interventions > Prednisolone > Oral > Analgesic equivalence to indomethacin or naproxen acute gout > Equivalence claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Rainer 2016 was a double-blind double-dummy active-control equivalence trial comparing prednisolone with indomethacin. Janssens 2008 compared prednisolone with naproxen and used a 118-participant completer primary analysis. Janssens was also an author on Rainer, so these do not represent separate-investigator replication.
Why this is classified as C (54)
Overlapping investigators and the two shared defects—equivalence design and active controls without placebo—give C with 54 points.
Counterpoint. C does not mean no effect; it reflects that the confirmed comparison is equivalence to NSAIDs rather than direct placebo superiority.
Rejudgment record. Cross-check applied — The two active-control equivalence trials shared an investigator, and no systemic-glucocorticoid-alone placebo trial was identified
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Pain relief equivalent to indomethacin at two hours | C | The result was within the 13-mm boundary, but there was no placebo arm. |
| Pain relief equivalent to naproxen at 90 hours | C | The 118-participant primary analysis met the prespecified equivalence range. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Rainer TH et al. 2016 | Multicenter double-blind double-dummy randomized active-control equivalence trial | 416 randomized, 208 per arm; 376 completed the two-hour assessment, 189 versus 187 | Hong Kong Government Health and Health Services Research Grant Committee | Two-hour change in 100-mm VAS pain at rest and with activity; prespecified equivalence margin 13 mm | Between-group difference -1.15 mm at rest (95% CI -3.14 to 0.83), P=0.79, and 0.10 mm with activity (-1.91 to 2.10), P=0.52; equivalence met. | Pivotal publicly funded active-control equivalence trial |
| Janssens HJEM et al. 2008 | Double-blind randomized active-control equivalence trial | 120 randomized, 60 per arm; 118 in the primary per-protocol analysis, 59 per arm | Academic study at Radboud University Nijmegen Medical Centre | Reduction in 100-mm VAS pain at 90 hours; prespecified equivalence range 10 mm | Reductions of 44.7 versus 46.0 mm, difference 1.3 mm (95% CI -9.8 to 7.1). | Equivalence trial sharing an investigator with Rainer |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-01).
Final verification and publication gate: Codex · Evidence date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Prednisolone x analgesic equivalence to indomethacin or naproxen in acute gout — Evidence Grade C·54. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/oral-prednisolone-acute-gout-pain-relief/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.